Navidea Biopharmaceuticals, Inc. (NAVBQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNavidea Biopharmaceuticals, Inc. (NAVBQ) trades at $0.0001. Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing precision immunodiagnostic agents and immunotherapeutics. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for NAVBQ: NAVBQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Navidea Biopharmaceuticals, Inc. (NAVBQ) Healthcare & Pipeline Overview
Navidea Biopharmaceuticals, Inc., operating in the biotechnology sector, focuses on precision immunodiagnostic agents and immunotherapeutics. Their Manocept platform targets the CD206 mannose receptor for diagnostic modalities and therapeutic delivery. Currently under Chapter 11 reorganization, the company faces significant financial and operational challenges within a competitive landscape.
What Is the Investment Thesis for NAVBQ?
Navidea Biopharmaceuticals, Inc. faces significant challenges given its Chapter 11 reorganization filing in October 2025. The company's negative profit margin of -23117.6% and gross margin of -259.4% highlight severe financial difficulties. While the Manocept platform and pipeline of immunodiagnostic agents and immunotherapeutics represent potential value, the company's ability to navigate bankruptcy proceedings and secure funding for continued development is uncertain. Upcoming clinical trial results for NAV3-33 (Phase III) and NAV3-32 (Phase 2b) in RA could serve as catalysts, but the high beta of -5.96 indicates extreme volatility. Investors should carefully consider the high-risk nature of this investment.
Based on FMP financials and quantitative analysis
NAVBQ Key Highlights
Market capitalization of $0.00B reflects the company's distressed financial state and Chapter 11 filing.
- Profit margin of -23117.6% indicates substantial losses and operational inefficiencies.
- Gross margin of -259.4% demonstrates that the cost of goods sold significantly exceeds revenue.
- Beta of -5.96 suggests the stock price moves inversely and with greater magnitude compared to the market, indicating high volatility.
- The company filed for Chapter 11 reorganization on October 1, 2025, introducing significant uncertainty about its future.
Who Are NAVBQ's Competitors?
NAVBQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NAVBQ's Key Strengths?
Proprietary Manocept platform.
- Pipeline of clinical-stage immunodiagnostic agents.
- Expertise in targeting the CD206 mannose receptor.
- Potential for expansion into immunotherapeutics.
What Are NAVBQ's Weaknesses?
Chapter 11 reorganization.
- Negative profit and gross margins.
- Limited financial resources.
- Dependence on clinical trial success.
What Are the Key Risks for NAVBQ?
Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 5 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Chapter 11 reorganization introduces significant uncertainty and risk of liquidation.
- Competition from larger biotechnology companies with greater resources.
- Regulatory hurdles and clinical trial failures could delay or halt product development.
- Inability to secure funding could jeopardize the company's operations.
- Limited liquidity and wide bid-ask spreads in the OTC market.
What Are NAVBQ's Competitive Advantages?
- Proprietary Manocept platform.
- Pipeline of clinical-stage immunodiagnostic agents.
- Intellectual property protection (patents).
- Expertise in targeting the CD206 mannose receptor.
What Does NAVBQ Do?
Navidea Biopharmaceuticals, Inc., founded in 1983 and headquartered in Dublin, Ohio, is a biopharmaceutical company specializing in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company's core technology revolves around the Manocept platform, which targets the CD206 mannose receptor expressed on activated macrophages. This platform is designed for various diagnostic modalities, including single-photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection. Additionally, Manocept is intended for the delivery of therapeutic compounds targeting macrophages and immune- and inflammation-involved diseases. Navidea's pipeline includes NAV3-31, which has completed Phase IIb clinical trials for rheumatoid arthritis (RA) imaging, focusing on evaluating imaging repeatability, reproducibility, and stability. NAV3-35 is also in Phase IIb clinical trial for RA imaging, NAV3-33 is in Phase III clinical trial for RA, and NAV3-32 is in Phase 2b trial for RA-involved joints. The company is also exploring the use of Tc99m tilmanocept for cardiovascular applications, Kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. Formerly known as Neoprobe Corporation until January 2012, Navidea filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025. This action reflects the company's ongoing financial challenges and efforts to restructure its operations and debt.
What Products and Services Does NAVBQ Offer?
- Develops precision immunodiagnostic agents.
- Develops precision immunotherapeutics.
- Focuses on the Manocept platform targeting the CD206 mannose receptor.
- Develops diagnostic modalities including SPECT and PET.
- Develops therapeutic compounds targeting macrophages.
- Targets immune- and inflammation-involved diseases.
- Conducts clinical trials for rheumatoid arthritis imaging.
How Does NAVBQ Make Money?
- Develops and commercializes diagnostic substances.
- Develops therapeutic programs.
- Out-licenses or partners its technology.
- Generates revenue through sales of diagnostic agents (historically).
What Industry Does NAVBQ Operate In?
Navidea Biopharmaceuticals, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like CRXM, GDBYF, GLSHQ, and GNBT are also active in the biotechnology space, focusing on various therapeutic areas and diagnostic technologies. The industry is driven by innovation and the development of novel therapies, but it also faces challenges related to funding, clinical trial success rates, and market access. Navidea's focus on immunodiagnostic agents and immunotherapeutics places it within a niche segment of the broader biotechnology market, but its financial struggles and Chapter 11 filing present significant hurdles.
Who Are NAVBQ's Key Customers?
- Hospitals and imaging centers.
- Research institutions.
- Pharmaceutical companies (potential partners).
- Patients requiring diagnostic imaging.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Navidea Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dublin, US. The company is led by CEO Craig A. Dais. NAVBQ has traded publicly since 1992.
Key Financial Metrics
Return on equity for Navidea Biopharmaceuticals, Inc. stands at 355.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.32 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Navidea Biopharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Navidea Biopharmaceuticals, Inc. has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 67.3% below estimates on average.
NAVBQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NAVBQ Latest News
No recent news available for NAVBQ.
NAVBQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NAVBQ.
Price Targets
Wall Street price target analysis for NAVBQ.
NAVBQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NAVBQ; grades run from A+ (80-100) to F (below 30).
Leadership: Craig A. Dais
CEO
Craig A. Dais serves as the CEO of Navidea Biopharmaceuticals, Inc. His background includes experience in managing teams and overseeing operations within the biopharmaceutical sector. With a focus on strategic leadership, Dais is responsible for guiding Navidea through its current challenges and restructuring efforts. His expertise is crucial in navigating the company's pipeline development and commercialization strategies.
Track Record: Under Craig A. Dais's leadership, Navidea has focused on advancing its clinical trials and exploring strategic alternatives amidst financial constraints. His tenure has been marked by efforts to maintain operations and pursue potential partnerships, despite the company's Chapter 11 filing. Key decisions have involved prioritizing pipeline development and seeking avenues for financial restructuring.
NAVBQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Navidea Biopharmaceuticals, Inc. does not meet the minimum financial standards or reporting requirements for the higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, bankrupt, or have limited information available to investors. Trading on the OTC Other tier carries significant risks compared to exchanges like the NYSE or NASDAQ, which have stricter listing requirements and greater regulatory oversight.
- OTC Tier: OTC Other
- Limited information and disclosure due to OTC Other tier status.
- High risk of delisting or trading suspension.
- Potential for price manipulation and fraud.
- Significant financial distress and Chapter 11 bankruptcy.
- Limited liquidity and wide bid-ask spreads.
- Verify the company's current legal status and Chapter 11 proceedings.
- Obtain and review any available financial statements and disclosures.
- Assess the company's ability to continue as a going concern.
- Evaluate the potential for restructuring and recovery.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Check for any regulatory actions or investigations.
- History as a publicly traded company (formerly Neoprobe Corporation).
- Development of the Manocept platform and pipeline of immunodiagnostic agents.
- Prior clinical trial activity and regulatory filings.
- Presence of a CEO and management team.
- Headquarters in Dublin, Ohio.
Common Questions About NAVBQ (Healthcare)
What do analysts say about NAVBQ stock?
Given Navidea Biopharmaceuticals, Inc.'s Chapter 11 reorganization filing and OTC Other tier status, formal analyst coverage is likely limited or non-existent. Key valuation metrics such as P/E ratio (-0.00) and market capitalization ($0.00B) are not meaningful in the current context.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available sources and may be limited due to the company's OTC status and Chapter 11 filing.
- Financial data may not be current or fully reliable.